Safety outcomes
RESOLUTION, INTRAOCULAR PRESSURE
There was no significant difference in the BCVA and IOP of both eyes at baseline and the 12-week visit between the rebamipide treatment arms and the placebo group (all 
Comparison of best-corrected visual acuity and intraocular pressure between the study groups (n = 220)BCVA, best corrected visual acuity; logMAR, logarithm of the Minimum Angle of Resolution.; IOP, intraocular pressure.* One-way analysis of variance